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ABSTRACT 
Objective: To explore patients’ and health professionals’ experiences of 
initiating insulin as part of the Treating to Target in Type 2 Diabetes (4-T) 
randomized controlled trial. 
Research Design & Methods:  Interviews were conducted with 45 trial 
participants and 21 health professionals and analyzed thematically.   
Results: Patients were generally ‘psychologically insulin receptive’ when 
approached to participate in 4-T. Receptiveness arose largely from personal 
experiences of observing prior treatments intensify and blood glucose control 
deteriorate over time, which led patients to engage with and accept the idea 
that their diabetes was progressive. Health professionals also fostered 
receptiveness by drawing on their clinical experience to manage patients’ 
anxieties about initiating insulin.  
Conclusions: Previous studies may have over emphasized the problem of 
psychological insulin resistance, and overlooked factors and treatment 
experiences which may promote insulin receptiveness amongst type 2 
patients. 
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According to the literature, psychological insulin resistance, resulting in delays 
in treatment initiation, can arise from patients’ feelings of personal failure to 
self-manage their diabetes effectively and their anxieties about injecting, and 
from health professionals’ clinical inertia and a lack of knowledge and 
experience of insulin therapy [1,2,3,4,5,6].  There is, however, limited 
qualitative research drawing upon patients’ and health professionals’ 
experiences of initiating insulin therapy.  We report findings from a qualitative 
study involving patients and health professionals who, through their 
participation in the Treating to Target in Type 2 Diabetes (4-T) trial, initiated 
insulin using randomized analogue insulin regimens (basal, prandial and 
biphasic) [7,8]. 
 
RESEARCH DESIGN AND METHODS 
Eleven of the 58 4-T centres were included in this study, selected to reflect 
diversity in centre size and geographical location. Patients and health 
professionals were recruited using an opt-in procedure.  Patients were 
purposively selected so that the sample  comprised equal numbers from 
across the trial’s three treatment arms; was broadly representative of the 
wider trial population in terms of age, gender and glycemic control (Table 1); 
and included trial participants with high and low final HbA1c results (range: 5.3 
– 9.9%).  At least one health professional from each centre was interviewed (9 
physicians and 12 nurses). 
 
The interviews - which explored (in-depth) participants’ understandings and 
experiences of insulin initiation - were informed by topic guides and allowed 
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participants to raise issues which they perceived as salient.  Interviews were 
conducted between October 2008 and July 2009, lasted between 40 minutes 
and 2 hours, were digitally recorded and fully transcribed.  Data collection and 
analysis ran concurrently, with themes and hypotheses identified in early 
interviews informing questions in later interviews, in line with a grounded 
theory approach [9]. Data were coded using methods of constant comparison 
[9]. A qualitative data-indexing package (QSR Nvivo 2) facilitated data coding 
and retrieval.  
 
RESULTS 
Key finding 
We had anticipated that negative beliefs about insulin, and resistance to start 
insulin therapy, would feature widely in patients’ accounts.  However, the vast 
majority were what we term ‘psychologically insulin receptive’ when 
approached to participate in 4-T.  Key factors which fostered receptiveness 
are explored below. 
 
Engaging with disease progression 
For the majority of patients, the first time that they had been recommended 
insulin had been immediately prior to trial enrolment.  Patients frequently 
claimed to have been upset, disappointed or shocked when advised that 
insulin was now needed. However, accounts of having personally failed to 
self-manage their diabetes – or resistance to initiating insulin - were extremely 
rare. Most described accepting that they required insulin because they 
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realized their diabetes had progressed. This realization arose from observing 
their oral glucose lowering medications (OGLMs) increase over time, often to 
maximum doses, and their glucose control deteriorate despite following their 
treatment regimens.  Experiences of undertaking self-monitoring of blood 
glucose (SMBG) or comparing successive HbA1c results facilitated patients’ 
engagement with their disease progression. Armed with these experiences, 
some reported actually approaching their physician and requesting insulin: 
 
 “The doctor said anything under ten [mmol/l] was acceptable ... I started 
testing my blood sugar levels and that was really when I began to realize that 
tablets weren't helping me. So I went to the doctor and said, ‘I want to go on 
insulin.’” (Pt20) 
 
Managing anxieties about insulin therapy 
Although psychologically receptive towards initiating insulin therapy, most 
patients described being anxious about the prospect of injecting.  In most 
cases, these anxieties appeared to have been managed effectively by health 
professionals, who were usually highly experienced in initiating insulin.  
Patients frequently reported being pleasantly surprised upon discovering that 
they would be using insulin pens.  These were seen as being more discrete, 
less painful to use, and easier to transport than the syringes they had 
anticipated using.  Nurses described how encouraging engagement with 
SMBG results, prescribing low starting doses of insulin and supervising initial 
injections were some of their tried-and-tested techniques for easing patients’ 
transition onto insulin.  The structured programme of face-to-face and 
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telephone support delivered as part of 4-T provided health professionals with 
opportunities to employ these practices, in order to coax more anxious trial 
participants through the initiation period: 
 
“I had one patient on the 4-T study who was not going to go on insulin 
because he was terrified of needles, and then I brought him in here and I said 
‘Well, let me show you’, you know, and I got him to do an injection and he said 
'I didn't feel anything' and then he came into the study.” (HCP 1) 
 
CONCLUSIONS 
Previous studies have placed strong emphasis on the need to overcome 
patients’ psychological insulin resistance, yet they have also shown that the 
majority of their study participants were, in fact, willing to initiate insulin.  For 
example, in one key paper focusing on psychological resistance to insulin, 
71.7 % of non-insulin treated type 2 patients were, to varying degrees, willing 
to initiate insulin therapy, with almost a quarter being ‘very willing’ [2].  Also, 
73% of patients randomized to the insulin arm of the UKPDS accepted 
treatment [10].  In line with these findings, our study suggests that 
receptiveness, rather than resistance, may be a more common experience 
amongst patients with type 2 diabetes.  It is possible, therefore, that previous 
research has over-emphasised the difficulties associated with resistance, to 
the detriment of exploring factors which can promote receptiveness.   
 
Encouraging SMBG at the point where insulin is being recommended, and 
educating patients about acceptable ranges for their readings, may help 
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promote psychological insulin receptiveness, as might discussion of HbA1c 
results in diabetes review visits.  Providing patients with insulin pens and a 
structured programme of support during initiation may also help patients to 
overcome their anxieties about insulin. 
 
Limitations of the study 
The study was limited to the United Kingdom.  The vast majority of 
interviewees were White-British.  By virtue of having agreed to participate in 
4-T, patients may have held more positive beliefs about insulin than those in 
non-trial settings. 
 
N.J., J.L. and NH researched data and wrote manuscript.  A.F. and R.R. 
contributed to discussion and reviewed/edited manuscript. 
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Table 1 Patient characteristics 
Patients 4-T 
(n=708) 
Qualitative 
sample 
(n=45) 
Age   
Mean age ( SD) 61.7 (9.8)* 64.7 ( 8.5) † 
   
Sex   
Male 454 29 
Female 254 16 
   
Randomisation   
Biphasic 235 15 
Prandial 239 15 
Basal 234 15 
   
Glycated hemoglobin at Yr 3   
Median HbA1c 6.9% 6.9% 
Number (%) of patients with HbA1c  7% 425 (60) 26 (58) 
Number (%) of patients with HbA1c  6.5% 283 (40) 19 (42) 
Notes 
* Age at trial initiation 
† Age at interview 
 
 
